Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
co-amoxiclav
- Development stage
- Phase 4
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Co-amoxiclav (Bristol Laboratories) is a combination antibiotic oral suspension containing amoxicillin trihydrate and potassium clavulanate. Amoxicillin is a beta-lactam antibiotic that exerts its bactericidal activity by binding to and inhibiting penicillin-binding proteins (PBPs), which are essential for bacterial cell wall synthesis. Clavulanic acid is a beta-lactamase inhibitor that structurally resembles beta-lactam antibiotics; it binds irreversibly to beta-lactamase enzymes produced by resistant bacteria, preventing them from inactivating amoxicillin. This combination extends the antibacterial spectrum of amoxicillin to include many bacteria normally resistant to it and other beta-lactam antibiotics. It is indicated for the treatment of various bacterial infections, including acute bacterial sinusitis, skin and soft tissue infections, and bone and joint infections.
- Brand names
- Co-amoxiclav Oral Suspension Sugar-Free
- Other names
- amoxicillin + clavulanic acidamoxicillin trihydrate + potassium clavulanate
02
Targets
β-lactamasePBP (Penicillin-binding protein family)
Beyond the preview
Go deeper on co-amoxiclav.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on co-amoxiclav.